ETON Chief Business Officer David Krempa Buys 10,000 Shares

On June 26, 2026, David Krempa, the Chief Business Officer of Eton Pharmaceuticals, Inc. (NasdaqGM: ETON), purchased 10,000 shares of the company. This insider purchase was not part of a pre-arranged trading plan. Shares of Eton Pharmaceuticals traded near $36.73 on Wednesday.

Insider Buying and Selling at Eton Pharmaceuticals, Inc.

In addition to David Krempa's recent purchase, other insiders have been active. On June 17, 2026, Jennifer McKie Adams bought 50,000 shares at $3.78 and sold the same amount at $32.48. Earlier, on May 28, 2026, President and CEO Sean Brynjelsen sold 120,000 shares at an average price of $31.88.

Other Institutional Activity in Eton Pharmaceuticals

Institutional investors have also shown interest in Eton Pharmaceuticals. Vanguard Capital Management LLC opened a new position with 994,089 shares valued at approximately $24.5 million. ECOR1 Capital, LLC increased its holdings by 141,394 shares, bringing its total to 2,171,938 shares worth about $53.6 million, marking a 7% increase. BlackRock, Inc., however, reduced its stake by 21,621 shares, now holding 1,717,286 shares valued at roughly $42.4 million, a 1.2% decrease.

Eton Pharmaceuticals, Inc. Stock Down 34.8%

Shares of Eton Pharmaceuticals traded near $36.73 on Wednesday. The company has a market cap of approximately $978 million and a forward P/E ratio of 19. Eton's stock has a beta of 0.889, indicating relatively low volatility. The 52-week low is $13.51, and the high is $35.99, with a 50-day moving average of $29.70 and a 200-day moving average of $21.12. The company's current ratio is 1.205, and its quick ratio is 0.749, with a debt-to-equity ratio of 102.113.

Recent Earnings

Eton Pharmaceuticals reported revenue of $86.9 million, showing a growth of 40.4%. However, the company has a negative net margin of -1.7% and a return on equity of -5.4%. The next earnings report is expected on August 6, 2026.

Analysts Set New Price Targets

Analysts have been bullish on Eton Pharmaceuticals. On May 15, 2026, HC Wainwright & Co. maintained a "buy" rating with a $57 price target. The consensus among three analysts is a "strong buy," with a mean price target of $45.67.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is a healthcare company based in Deer Park, Illinois. It focuses on developing and commercializing treatments for rare diseases. The company's product lineup includes treatments for conditions such as adrenal insufficiency and Wilson disease. Eton, led by CEO Sean E. Brynjelsen, employs 44 people.

Bottom Line

David Krempa's purchase of Eton Pharmaceuticals shares highlights insider confidence in the company. Eton's focus on rare disease treatments makes it a noteworthy player in the healthcare sector. Institutional activity and analyst ratings suggest continued interest in the stock. As a reminder, insider and institutional data like this is often backward-looking and may not reflect current positions.